Lineage Therap (BT3) Price & Analysis

1 Followers

BT3 Stock Chart & Stats

€0.92

€0.03(3.17%)

At close: Jul 29 4:00 PM EDT

€0.92

€0.03(3.17%)

Day’s Range― - ―

52-Week Range€0.78 - €1.68

Previous CloseN/A

Volume0.00

Average Volume (3M)36.00

Market Cap

€219.01M

Enterprise Value€292.88M

Total Cash (Recent Filing)€50.83M

Total Debt (Recent Filing)€2.30M

Price to Earnings (P/E)―

Beta0.87

Next Earnings

Nov 05, 2026

EPS Estimate

-0.03

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.14

Shares Outstanding252,907,470

10 Day Avg. Volume0

30 Day Avg. Volume36

Financial Highlights & Ratios

PEG Ratio-0.03

Price to Book (P/B)8.63

Price to Sales (P/S)26.40

P/FCF Ratio-19.77

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€5.58

Price Target Upside506.20% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

EPS Forecast (FY)-0.05

Revenue Forecast (FY)€13.50M

Bulls Say, Bears Say

Bulls Say

Scalable Manufacturing PlatformValidated GMP banking and production provides a reusable foundation for multiple cell types and programs. If the platform continues to support scalable, lower-cost allogeneic manufacturing, it can shorten development timelines, improve consistency, and strengthen Lineage’s long-term partnering appeal.

Strategic Partnerships And Milestone PotentialEstablished collaborations provide external validation, development support, and potential non-dilutive economics across the pipeline. Roche/Genentech and Demant involvement may reduce the burden of independently funding programs while preserving milestone and royalty opportunities if therapies advance.

Conservative Balance Sheet And Extended RunwayLow leverage limits near-term balance-sheet pressure and preserves flexibility while clinical programs progress. Combined with management’s projected runway into Q3 2028, the company has more time to pursue milestones and partnerships before needing additional financing, although execution remains important.

Bears Say

Persistent Cash Burn And Operating LossesOngoing negative operating and free cash flow means Lineage currently consumes capital rather than funding development internally. Persistent losses can reduce financial flexibility over time and increase reliance on financings, milestones, or partnerships to sustain clinical and platform investment.

Declining Collaboration RevenueThe revenue decline highlights the variability of Lineage’s collaboration-based business model before product commercialization. Lower recognized partnership revenue can make operating results less predictable, constrain internal funding capacity, and increase dependence on future milestones or new agreements.

Major ILT1 Manufacturing Scale ChallengeThe substantially higher cell requirement creates a material technical and execution hurdle for ILT1. Lower islet-cell proliferative capacity and the need to scale production could delay development, raise manufacturing complexity, and limit the program’s ability to progress efficiently toward clinical use.

Lineage Therap News

Lineage Cell announces issuance of patent underlying AlloSCOPE 5D platform

Lineage Cell Therapeutics (LCTX) announced that the United States Patent and Trademark Office, USPTO, has issued U.S. Patent...

2M ago

LCTX

Lineage Cell Therapeutics management to meet with B. Riley

Meeting to be held on August 25 in San Francisco and in Los Angeles on August 26 hosted...

2M ago

LCTX

Lineage Maintained at Buy with Unchanged $3 Target as Cell Therapy Pipeline and DOSED SCI Trial Advance

Lineage Therap, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Michael Okunewitch from...

2M ago

LCTX

Lineage Cell Therapeutics Balances Progress and Risk

Lineage Cell Therapeutics, Inc. (($LCTX)) has held its Q2 earnings call. Read on for the main highlights of...

3M ago

LCTX

Lineage Maintained at Buy as Analyst Cites Clinical Momentum and Strategic Backing; $9 Price Target Reaffirmed

Analyst John Newman from Canaccord Genuity maintained a Buy rating on Lineage Therap and keeping the price target...

3M ago

LCTX

Lineage Cell Therapeutics reports Q2 EPS (3c), consensus (3c)

Reports Q2 revenue $1.069M, consensus $1.53M. “As we continue to support our collaboration with Roche and Genentech for...

3M ago

LCTX

LCTX Upcoming Earnings Report: What to Expect?

Lineage Cell Therapeutics, Inc. (LCTX) is scheduled to report 2nd quarter earnings on 08/06/2026, after the market closes....

3M ago

LCTX

Lineage Cell Therapeutics provides update on COR1 program

Lineage Cell provided an update on COR1, the Company’s allogeneic corneal endothelial cell transplant program, in preclinical development...

3M ago

LCTX

Lineage Cell Shareholders Reaffirm Governance and Executive Pay

An announcement from Lineage Therap ( ($LCTX) ) is now available. At its annual meeting of shareholders held...

4M ago

LCTX

Lineage Cell Therapeutics Highlights R&D Momentum Amid Losses

Lineage Cell Therapeutics, Inc. (($LCTX)) has held its Q1 earnings call. Read on for the main highlights of...

5M ago

LCTX

Lineage Cell Therapeutics reports Q1 EPS (3c), consensus (2c)

Reports Q1 revenue $1.73M, consensus $3.6M. “This quarter, we continued to build on our developmental and clinical accomplishments....

5M ago

LCTX

Lineage Cell sees cash, equivalents funding operations into 2Q28

16:04 EDT Lineage Cell sees cash, equivalents funding operations into 2Q28 Published first on TheFly – the ultimate...

5M ago

LCTX

Options Volatility and Implied Earnings Moves Today, May 12, 2026

Today, several major companies are expected to report earnings: Lineage Therap (LCTX), Achieve Life Sciences (ACHV), Zebra Tech...

5M ago

LAR

OGI

LCTX Earnings Report this Week: Is It a Buy, Ahead of Earnings?

Lineage Cell Therapeutics, Inc. (LCTX) is scheduled to report 1st quarter earnings on 05/07/2026. Regarding Q1 estimates, Wall...

6M ago

LCTX

BT3 FAQ

What was Lineage Cell Therapeutics, Inc.’s price range in the past 12 months?

Lineage Cell Therapeutics, Inc. lowest stock price was €0.78 and its highest was €1.68 in the past 12 months.

What is Lineage Cell Therapeutics, Inc.’s market cap?

Lineage Cell Therapeutics, Inc.’s market cap is €219.01M.

When is Lineage Cell Therapeutics, Inc.’s upcoming earnings report date?

Lineage Cell Therapeutics, Inc.’s upcoming earnings report date is Nov 05, 2026 which is in 13 days.

How were Lineage Cell Therapeutics, Inc.’s earnings last quarter?

Lineage Cell Therapeutics, Inc. released its earnings results on Aug 06, 2026. The company reported -€0.027 earnings per share for the quarter, missing the consensus estimate of -€0.025 by -€0.002.

Is Lineage Cell Therapeutics, Inc. overvalued?

According to Wall Street analysts Lineage Cell Therapeutics, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Lineage Cell Therapeutics, Inc. pay dividends?

Lineage Cell Therapeutics, Inc. does not currently pay dividends.

What is Lineage Cell Therapeutics, Inc.’s EPS estimate?

Lineage Cell Therapeutics, Inc.’s EPS estimate is -0.03.

How many shares outstanding does Lineage Cell Therapeutics, Inc. have?

Lineage Cell Therapeutics, Inc. has 252,907,470 shares outstanding.

What happened to Lineage Cell Therapeutics, Inc.’s price movement after its last earnings report?

Lineage Cell Therapeutics, Inc. reported an EPS of -€0.027 in its last earnings report, missing expectations of -€0.025. Following the earnings report the stock price went down -1.043%.

Which hedge fund is a major shareholder of Lineage Cell Therapeutics, Inc.?

Currently, no hedge funds are holding shares in DE:BT3

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Lineage Therap Stock Smart Score

Underperform

Fundamentals

Return on Equity

-71.14%

Trailing 12-Months

Asset Growth

16.98%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries. It also offers ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of sensorineural hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company is developing RND1, a novel hypoimmune induced pluripotent stem cell line for the development of a cell transplant candidate for the potential treatment of an undisclosed indication, as well as engages in the research and development of ILT1, an allogeneic cell transplant for the treatment of Type 1 Diabetes; and LCT-CON, an allogeneic cell transplant, as well as therapeutic products for retinal diseases, neurological diseases, ophthalmology, metabolic, and disorders and oncology. The company has a collaboration agreement with William Demant Invest for the preclinical development of ReSonance (ANP1). It also has a strategic collaboration with Factor Bioscience Inc. for the development of genetically engineered iPSC line for the company to utilize for differentiation into certain cell transplant product candidates. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.

Lineage Therap (BT3) Earnings & Revenues

Historic Earnings Reports

BT3 Earnings Call

Q2 2026

0:00 / 0:00

Earnings Call Sentiment|Neutral

The call presented meaningful technical and strategic progress: demonstrated scalable GMP manufacturing (AlloSCOPE), rapid internal pipeline expansion (COR1, ILT1, ReSonance), and partnership validation (Roche/Genentech, Demant). Financial reporting showed an apparent improvement to net income, extension of cash runway into Q3 2028, and an incremental $4.6M ATM raise. However, material weaknesses and near-term risks remain: Q2 revenue dropped substantially (~60.7% YoY), reported profitability was driven by noncash accounting items, cash runway still depends on contingent exercises/milestones, OpRegen advancement timing is dependent on partner-driven surgical optimization, and ILT1 faces major manufacturing scale challenges. Overall, positives around technology, partnerships and program breadth are tempered by funding, revenue dynamics and technical/partner-dependent execution risks.View all DE:BT3 earnings summaries

BT3 Stock 12 Month Forecast

Average Price Target

€5.58

▲(506.20% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"€4","9":"€9","-1":"-€1","1.5":"€1.5","6.5":"€6.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":8.03088144,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€8.03</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5.577001,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€5.58</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2.67696048,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€2.68</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,1.5,4,6.5,9],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.84,1.393144726153846,1.9462894523076923,2.4994341784615384,3.0525789046153844,3.6057236307692304,4.158868356923077,4.712013083076923,5.265157809230769,5.818302535384615,6.371447261538461,6.924591987692307,7.477736713846154,{"y":8.03088144,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.84,1.2043846923076922,1.5687693846153845,1.9331540769230768,2.297538769230769,2.6619234615384615,3.026308153846154,3.390692846153846,3.7550775384615385,4.119462230769231,4.483846923076923,4.8482316153846154,5.212616307692308,{"y":5.577001,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.84,0.9813046523076923,1.1226093046153847,1.2639139569230768,1.4052186092307692,1.5465232615384616,1.6878279138461538,1.8291325661538462,1.9704372184615386,2.111741870769231,2.253046523076923,2.3943511753846156,2.535655827692308,{"y":2.67696048,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.39,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.56,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.47,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.35,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.21,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.68,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.33,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.21,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.11,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.114,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.941,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.921,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.84,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >